Meningitis and septicaemia are serious, life-threatening illnesses that can kill within hours. The Meningitis Research Foundation (MRF) is the leading UK, Irish and international charity working to bring together people and expertise to defeat these diseases. In this exclusive interview, we speak with Vinny Smith, Chief Executive, to hear about their vital work, key achievements and future plans.

To begin, please tell us how the MRF came to fruition.

MRF was founded by a family who tragically lost their son to meningitis just over 30 years ago. Driven by this awful experience, they decided it was important to set up a charity that could raise awareness and increase research into the disease so that other families did not have to go through what they had.

You became the Chief Executive of the MRF in 2015, bringing with you a wealth of diverse leadership experience. What are your aims for MRF?

Our aims are driven by the families we support. They ask us to help prevent new cases, to ensure those who do get the disease are diagnosed and treated effectively by trained and resourced health workers, and to make sure people have the information, advice and support they need. We achieve this by enabling research that supports better policy and by transforming engagement in meningitis as an issue from global policy right down to individuals and the support they need. If we’re successful, this will ensure MRF stays the world’s leading meningitis charity.

What would you say are MRF’s most important achievements to date?

When MRF was founded, outbreaks in the UK and Ireland were at far higher levels than they are today. Thanks to our work and our partners, rates in the UK and Ireland have come down significantly since then through the introduction of new and effective vaccines. This is an incredible achievement that we and our supporters played a major role in achieving. Over the past 3 years we built on this great platform and in November last year the World Health Assembly passed its first ever resolution on meningitis with a goal to defeat the disease by 2030. We led the calls for this to happen and have been instrumental in the process.

How does MRF support research? What types of research do you focus on?

We support research in four ways. By convening people and expertise through research conferences, meetings and the Global Meningitis Genome Partnership for which we are the secretariat. We directly fund research, for example, into genomics building on the success of the MRF Meningococcal Genome Library and Global Meningitis Genome Library. We partner on research into long term impact of meningitis in people’s lives. And we create and share the best available data and evidence on progress being made against meningitis around the world through the Meningitis Progress Tracker.

How is the general public involved in your work?

Our supporters and public shape our whole strategy and approach. In the past three years they have been instrumental in guiding the priorities of the new global roadmap for meningitis and we have just finished consulting with them about our next 5-year strategy. They have also often been directly involved in research as participants in studies or trials. On top of that, they are the most incredible advocates for change, holding policy makers to account and demanding change.

We are, of course, in the midst of the COVID-19 pandemic. How has this affected the work of MRF?

As an organisation everything has changed. As with most other charities, our income has dramatically decreased for the time being because supporters cannot fundraise like they used to because of lockdown measures that have to be in place. This means we have had to reduce our investment in research, make some people redundant, move office, work from home, and put some work on hold as a result. But what drives us and what motivates our team and our supporters and the public hasn’t changed at all. That’s why, with their help, we’re still here and with the news of coming vaccine programmes we continue to be optimistic about our work.

Finally, looking now to the future, MRF has the stated aim of defeating meningitis by 2030. What will this ambitious goal involve over the next ten years?

In short it requires the largest global collaborative effort for meningitis ever attempted. It will mean ending epidemics; dramatically reducing new preventable cases; and ensuring the people who do survive with after affects including disability get the support they need. This requires better use of and access to existing vaccines as well as new vaccines. It requires better diagnosis and treatment, including new rapid diagnostic tests. It requires better surveillance and data on the disease and its impact. It needs support for people living with the often lifetime impact of ‘surviving’. It requires engagement, advocacy and awareness for policy makers and citizens to deliver change on the ground. And of course it will need funding – lots of it.

W: https://www.meningitis.org/

Twitter: @M_R_F

Reference
https://doi.org/10.33548/SCIENTIA618

Want to republish our articles?

 

We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more

Creative Commons Licence
(CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.


More articles you may like

Dr Uwe Grether – Targeting the Cannabinoid CB2 Receptor for Novel Anti-inflammatory Therapeutics

Dr Uwe Grether – Targeting the Cannabinoid CB2 Receptor for Novel Anti-inflammatory Therapeutics

On the surface of many of our cells, intriguing receptors called cannabinoid receptors reach out into their environment. The CB2 subtype of this receptor family is expressed largely on our immune cells and plays an important role in inflammatory responses, making it a promising target for anti-inflammatory therapeutics. To produce effective drugs, the molecules that bind to the CB2 receptor, known as ligands, need to be characterised. Dr Uwe Grether from F. Hoffmann-La Roche Ltd has dedicated his research to discovering useful CB2 receptor ligands and utilising them in the development of novel anti-inflammatory therapeutics.

Dr Uwe Grether – Targeting the Cannabinoid CB2 Receptor for Novel Anti-inflammatory Therapeutics

Professor Peter Breunig – The Significance of Nok Culture Sculptures in Nigerian Prehistory

Peter Breunig is a Professor of Archaeology at Goethe University in Frankfurt, Germany. He has spent much of his recent career conducting in-depth analyses around the Nok culture, a prehistoric society based in central Nigeria. Much of his research has focused on uncovering the mystery surrounding elaborate terracotta sculptures, made by the Nok people over 2,500 years ago. Whilst there is much speculation around their purpose, Peter Breunig and his team have identified a spatial proximity to burial sites, indicating their usage in funeral rituals.

The Biomedical Entrepreneurship Skills Development Program (BEEP): Educating a New Generation of Medical Innovators

The Biomedical Entrepreneurship Skills Development Program (BEEP): Educating a New Generation of Medical Innovators

Innovative, new technologies are rapidly being introduced into the medical world, as scientists and inventors continually discover solutions to all kinds of health issues. However, comprehensive education in medical product development, business process and strategy is distinctly lacking for science students who aspire to become commercial medical innovators and entrepreneurs. Entrepreneurially minded professionals at the New York University Grossman School of Medicine developed, implemented, and integrated programs to train early scientists in the business side of science to accelerate the pace of commercialisation and encourage individuals to pursue venture creation and entrepreneurship to impact highly relevant healthcare solutions.

Jenna Rackovan – Helping Fish Near Power Plants to Just Keep Swimming

Jenna Rackovan – Helping Fish Near Power Plants to Just Keep Swimming

Cleaner, greener electricity is imperative to meet the demands of a burgeoning population. Many power plants rely on vast quantities of water to cool their systems and maintain proper operation. But sucking up vast quantities of water can pose a risk for fish and other aquatic animals. Balancing the operational efficiency of power plant cooling systems with environmental protection requires a dedicated team of engineers and fisheries biologists. In their recent research, Jenna Rackovan and her colleagues at Alden Research Laboratory in Massachusetts optimise the use of travelling water screens for fish protection.